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Article

MARCH1 protects the lipid raft and tetraspanin web
from MHCII proteotoxicity in dendritic cells
Jaehak Oh,1,2 Justin S.A. Perry,3 Heather Pua,2,3 Nicole Irgens‑Möller,1,2 Satoshi Ishido,5 Chyi‑Song Hsieh,4 and
Jeoung‑Sook Shin1,2
of Microbiology and Immunology, 2Sandler Asthma Basic Research Center, and 3Department of Pathology, University of California, San Francisco,
San Francisco, CA
4Department of Internal Medicine, Division of Rheumatology, Washington University School of Medicine, St. Louis, MO
5Department of Microbiology, Hyogo College of Medicine 1-1, Mukogawa-cho, Nishinomiya, Japan

Dendritic cells (DCs) produce major histocompatibility complex II (MHCII) in large amounts to function as professional
antigen presenting cells. Paradoxically, DCs also ubiquitinate and degrade MHCII in a constitutive manner. Mice deficient in the MHCII-ubiquitinating enzyme membrane-anchored RING-CH1, or the ubiquitin-acceptor lysine of MHCII,
exhibit a substantial reduction in the number of regulatory T (Treg) cells, but the underlying mechanism was unclear. Here
we report that ubiquitin-dependent MHCII turnover is critical to maintain homeostasis of lipid rafts and the tetraspanin
web in DCs. Lack of MHCII ubiquitination results in the accumulation of excessive quantities of MHCII in the plasma
membrane, and the resulting disruption to lipid rafts and the tetraspanin web leads to significant impairment in the
ability of DCs to engage and activate thymocytes for Treg cell differentiation. Thus, ubiquitin-dependent MHCII turnover
represents a novel quality-control mechanism by which DCs maintain homeostasis of membrane domains that support
DC’s Treg cell–selecting function.
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Introduction
Membrane-anchored RING-CH1 (MAR
CH1) is a membrane-anchored ubiquitin ligase expressed in hematopoietic
cells, particularly antigen presenting cells (Matsuki et al., 2007).
It is composed of an N-terminal cytoplasmic tail that possesses
a catalytic RING domain, two transmembrane domains that interact with a specific substrate, and a C-terminal cytoplasmic
tail. Upon recognition of substrate, MARCH1 brings a ubiquitinated E2 ubiquitin-conjugating enzyme into close proximity of
its RING domain and substrate and catalyzes ubiquitin transfer
from E2 to substrate. Transferred ubiquitin molecules serve as
a signaling motif for endocytosis and lysosomal sorting, resulting in internalization and lysosomal degradation of the substrate
(Lehner et al., 2005; Ohmura-Hoshino et al., 2006).
Several immune-associated molecules have been shown
to be endocytosed and degraded in cells overexpressing MAR
CH1 (Bartee et al., 2004). However, major histocompatibility
complex II (MHCII) and CD86 are the only molecules shown
to be ubiquitinated by MARCH1 under physiological conditions (Matsuki et al., 2007; De Gassart et al., 2008; Baravalle
et al., 2011). MHCII has an evolutionally conserved lysine in
the cytoplasmic tail in its β-chain, and this lysine is targeted for
ubiquitination (Shin et al., 2006; van Niel et al., 2006; Oh and
Shin, 2015). CD86 has multiple lysines in the cytoplasmic tails,
and many of these lysines can be ubiquitinated (Baravalle et
al., 2011; Corcoran et al., 2011). In accordance with the role of
MARCH1 in mediating ubiquitination and endocytosis of MHC
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II and CD86, MARCH1 ablation resulted in a marked increase
in the surface expression of these two molecules in dendritic
cells (DCs) in mice. Interestingly, these mice exhibited a significant reduction in the number of regulatory T (Treg) cells
in the thymus (Oh et al., 2013). More interestingly, mice deficient in the cytoplasmic lysine (K) of MHCII (called “MHCII
K” here) exhibited a similar deficiency in thymic Treg cells (Oh
et al., 2013). Furthermore, DCs deficient in MARCH1 or MHC
II K were defective at differentiating immature thymocytes to
Treg cells in vitro (Oh et al., 2013). This finding suggests that
MHCII ubiquitination plays an important role in DC function
of selecting Treg cells. However, the underlying mechanisms
have not been identified.
Treg cells are selected through a cognate interaction of
CD4+ thymocytes with thymic antigen-presenting cells, and the
strength of this interaction is one of the key determinants for
Treg cell selection (Hsieh et al., 2012; Stritesky et al., 2012;
Klein et al., 2014). Low-avidity interaction does not relay sufficient signal to interacting thymocytes for expression of foxp3,
the key transcription factor that guides Treg cell differentiation,
whereas high-avidity interaction triggers apoptotic cell death
resulting in negative selection of the interacting thymocytes.

© 2018 Oh et al. This article is distributed under the terms of an Attribution–Noncommercial–
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Figure 1. DC expression of MARCH1 is important for Treg cell development in the thymus. (A) The amount of loxp-flanked MARCH1
genomic DNA (gDNA) in Sirpα− thymic DCs,
Sirpα+ thymic DCs, thymic B cells, and thymic
epithelial cells (TECs) in MARCH1fl/fl CD11cCRE mice relative to MARCH1fl/fl mice. Each
cell type was isolated by FACS as described
previously (Oh et al., 2013). Data are averaged from three individual mice. (B) Surface
expression of MHC
II in Sirpα− and Sirpα+
thymic DCs of MAR
CH1fl/fl, MARCH1fl/fl
CD11c-CRE, MARCH1−/−, and MHC
IIK>R/K>R
mice. Data represent three independent experiments. (C) Numbers of total, CD4−CD8− (DN),
CD4+CD8+ (DP), CD4+CD8− (CD4SP), and
CD4−CD8+ (CD8SP) thymocytes and Treg cells
(CD4+CD8−Foxp3+CD25+) in MARCH1fl/fl and
MARCH1fl/fl CD11c-CRE mice. Each circle
represents an individual mouse. Error bars represent SEM. **, P < 0.01.

Results
DC expression of MARCH1 is important
for Treg cell development in the thymus

To determine the extent to which DCs contribute to the role
of MARCH1 in promoting Treg cell development in vivo, we
generated mice with loxP-flanked alleles of the RING domain of MARCH1 and bred them to CD11c-CRE transgenic
mice expressing CRE recombinase under the control of the
CD11c promoter (MARCH1fl/fl CD11c-CRE mice, Fig. S1).
The loxP-flanked region of MAR
CH1 was efficiently and
specifically deleted in DCs of MARCH1fl/flCD11c-CRE mice
(Fig. 1 A). DCs in these mice expressed MHCII at markedly
elevated levels, similar to DCs from MARCH1-deficient mice
(MARCH1−/−) or MHCII K–deficient mice (MHCIIK>R/K>R, the
2
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mice in which the ubiquitin acceptor lysine K of MHCII was
replaced with arginine [R]; Fig. 1 B). MARCH1fl/flCD11c-CRE
mice had a normal number of total, CD4−CD8−, CD4+CD8+,
CD4+CD8−, and CD4−CD8+ thymocytes, but the number of
Treg cells was reduced by approximately half (Fig. 1 C), similarly to what has been observed in MARCH1−/− mice and MHC
IIK>R/K>R mice (Oh et al., 2013). Thus, the role of MARCH1
in promoting Treg cell development is critically dependent on
MARCH1 expressed in DCs.
MARCH1-mediated MHCII ubiquitination is
required for DCs to effectively engage and
activate thymocytes

We have previously shown that DCs deficient in MARCH1
were poor at differentiating immature thymocytes into Treg
cells in vitro. To determine how MARCH1 deficiency impairs
DC function of developing Treg cells, we examined whether
MARCH1 is important for DCs to stably engage thymocytes
and provide sufficient stimulatory signal for activation. DCs
were isolated from thymi of MARCH1-deficient mice, loaded
with ovalbumin, and co-cultured with CD4+ thymocytes isolated from the mice expressing ovalbumin-specific T cell receptor (TCR; OT-II mice). 3 h later, the number of DCs that formed
stable conjugate with thymocytes was determined by flow cytometry. We found that MARCH1-deficient DCs were engaged
by thymocytes to a lower frequency than WT DCs (Fig. 2, A
and B). 24 h later, we also determined the expression of CD69
and CD25 in thymocytes, specific indicators of thymocyte activation involving early and late TCR signaling, respectively. We
found that the thymocytes cultured with MARCH1-deficient
DCs expressed CD69 to a significantly lower frequency than
those cultured with WT DCs (Fig. 2, C and D). The thymocytes
that had been cultured with MARCH1-deficient DCs and expressed CD69 were found to express lower levels of CD25 than
those cultured with WT DCs. (Fig. 2, C and E). These findings
indicate that MARCH1 is required for DCs to stably engage
thymocytes and provide them with strong and/or sustained
signal for activation. It is noteworthy that MARCH1-deficient
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Only the intermediate-avidity interaction delivers a signal appropriate for Treg cell differentiation.
DCs deficient in MAR
CH1 or the MHC
II K display
peptide-loaded MHCII (pMHCII) at much larger amounts than
WT DCs on the surface (Walseng et al., 2010; Oh et al., 2013).
Because pMHCII is the molecule that mediates a cognate interaction of DCs with CD4+ thymocytes, an increase in pMHCII in
DCs will increase DC avidity for antigen-specific thymocytes.
The increased avidity is then likely to drive the thymocytes to
apoptotic cell death while repressing differentiation into Treg
cells. However, the mice deficient in MARCH1 or MHCII K did
not show any increase in apoptotic cell death of CD4+ thymocytes or Treg cells (Oh et al., 2013). Furthermore, lowering the
amount of the peptide loaded onto MHCII did not restore the
development of Treg cells in MARCH1 or MHCII K–deficient
mice (Oh et al., 2013). This finding suggests that the role of
MARCH1 in supporting DC function of selecting Treg cells
is independent of controlling surface expression of pMHCII.
In this study, we have investigated the specific mechanism by
which MAR
CH1-dependent MHC
II ubiquitination supports
DC selection of Treg cells.
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Figure 2. MARCH1 or MHCII K–deficient DCs are incompetent to stably engage and sufficiently activate CD4+ thymocytes. (A–E) DCs were isolated from
WT or MARCH1−/− mouse thymi and co-cultured with CD4+CD8− thymocytes isolated from OT-II mice in the presence of increasing concentrations of ovalbumin. After 3 h, the percentage of DCs that formed a stable conjugate with thymocytes was determined by flow cytometry as described in Materials and
methods. The representative contour plots are shown in A, and the quantitative summary is shown in B. After 24 h, the expression of CD69 and CD25 in
thymocytes was determined by flow cytometry. The representative contour plots are shown in C. The percentages of thymocytes that expressed CD69 are
shown in D, and the level of CD25 expressed in the CD69+ thymocytes (geometric mean fluorescence intensity [gMFI]) are shown in E. (F–H) DCs were
isolated from WT or MHCIIK>R/K>R mouse thymi, co-cultured with CD4+CD8− thymocytes isolated from OT-II mice in the presence of increasing concentrations
of ovalbumin, and examined as described in the previous section. The percentage of DCs that formed a stable conjugate with thymocytes is shown in F, the
percentage of thymocytes that expressed CD69 is shown in G, and the level of CD25 expressed in CD69+ thymocytes is shown in H. Data points represent
two to three independent experiments with duplicate or triplicate per condition. Error bars represent SEM. *, P < 0.05; **, P < 0.01.

DCs were not much different from DCs of WT mice for the
level of expression of the costimulatory molecule CD80 and
the adhesion molecule ICAM1 (Fig. S2 A).
Next, we examined whether the role of MARCH1 in promoting DC engagement and activation of thymocytes depends
on its activity of mediating ubiquitination of MHCII. For this
examination, DCs were isolated from thymi of MHCIIK>R/K>R
mice and analyzed as described earlier. Similar to MARCH1deficient DCs, MHCII K–deficient DCs engaged and activated
thymocytes less efficiently than WT DCs (Fig. 2, F–H). MHC
II K–deficient DCs were not altered for the expression of CD86,
CD80, and ICAM-1 compared with WT DCs (Fig. S2 B). This
finding indicates that the effect of MARCH1 in promoting DC
engagement and activation of thymocytes is largely dependent
on its ability to ubiquitinate MHCII.

The presence of too many MHCII molecules,
not the absence of ubiquitinated MHCII,
is responsible for poor engagement and
activation of thymocytes by MHCII K–
deficient DCs

To identify the specific mechanism by which MHCII ubiquitination supports DC engagement and activation of thymocytes,
we used bone marrow–derived DCs (BMDCs), which showed
a similar dependence on MHCII ubiquitination to engage and
activate thymocytes (Fig. 3, B–D). We first tested whether toohigh expression of MHCII or the absence of ubiquitinated MHC
II is responsible for the poor engagement and activation of thymocytes by MHCII K–deficient DCs. To reduce surface MHC
II levels without introducing MHCII ubiquitination, we crossed
MHCIIK>R/K>R mice to MHCII−/− mice and derived BMDCs from
Role of MARCH1 in plasma membrane homeostasis • Oh et al.
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resulting MHCIIK>R/− mice. These BMDCs expressed MHCII at
slightly lower levels than BMDCs from MHCIIK>R/K>R mice on
the surface (Fig. 3 A). Interestingly, these DCs engaged thymocytes significantly better than DCs derived from MHCIIK>R/K>R
mice, suggesting that too-high MHCII, not the absence of ubiquitinated MHCII, exerted a negative impact on the ability of
DCs to engage thymocytes (Fig. 3 B). DCs derived from MHC
IIK>R/− mice also activated thymocytes more effectively than
DCs derived from MHCIIK>R/K>R mice, although the degree of
improvement was marginal (Fig. 3, C and D).
To further reduce surface MHCII levels in DCs, we expressed in DCs MHCII WT and MHCII (K>R) mutants using
an exogenous promoter. BMDCs were cultured from MHC
4
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II−/− mice and transduced with the retrovirus encoding MHC
II WT or MHCII (K>R) mutant (Shin et al., 2006). The retrovirus encoding MHCII WT successfully drove the expression
of MHCII in DCs (Fig. 3 E), but the level was low as ∼3% of
the level expressed by the endogenous promoter (Fig. 3 F).
DCs transduced with the retrovirus encoding MHCII (K>R)
mutant expressed much higher levels of MHCII than DCs
transduced with the retrovirus encoding MHCII WT but did
not reach to the level expressed by DCs derived from WT
mice (Fig. 3 F). Remarkably, we found that the DCs transduced with the retrovirus encoding MHCII (K>R) mutant
were superior to DCs transduced with the retrovirus encoding
MHCII WT both at engaging and at activating thymocytes
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Figure 3. The presence of too many MHCII molecules, not the absence of ubiquitinated MHCII, is responsible for poor engagement and activation of thymocytes by MHCII K-deficient DCs. (A–D) BMDCs were derived from WT, MHCIIK>R/K>R, and MHCIIK>R/− mice. The surface expression of MHCII is shown in
A. The BMDC was cultured with CD4+CD8− thymocytes isolated from OT-II mice in the presence of increasing concentrations of OVA323-339 peptide. The
percentage of DCs that formed stable conjugates with thymocytes is shown in B. The percentage of thymocytes that expressed CD69 is shown in C. The
level of CD25 expressed in CD69+ thymocytes is shown in D. (E and F) BMDCs were derived from MHCIIβ−/− mice and transduced with retrovirus encoding MHCIIβ WT or MHCIIβ (K>R) mutant along with cytosolic GFP. The efficiency of transduction and the expression of MHCII in transduced cells were
determined by flow cytometry. The representative dot plots are shown in E (cells transduced with retrovirus encoding MHCII WT and MHCII [K>R] mutant
are shown in left and right, respectively). The expression level of GFP and MHCII in transduced cells is shown in F (left and right panel, respectively). The
level of MHCII expressed in DCs derived from WT mice was overlaid for comparison (blue in the right panel of F). The MFI of the MHCII stain in DCs
transduced with retrovirus encoding MHCII WT and DCs derived from WT mice is indicated in F. (G–I) BMDCs were derived from MHCIIβ−/− mice and
transduced with retrovirus encoding MHCIIβ WT or MHCIIβ (K>R) mutant along with cytosolic GFP. Transduced cells (GFP+ cells) were isolated by FACS
and cultured with CD4+CD8− thymocytes isolated from OT-II mice in the presence of increasing concentrations of OVA323-339 peptide. The percentage of
DCs that formed stable conjugates with thymocytes is shown in G. The percentage of thymocytes that expressed CD69 is shown in H. The level of CD25
expressed in CD69+ thymocytes is shown in I. Data represent at least three independent experiments with triplicates for each condition. Error bars represent
SEM. *, P < 0.05; **, P < 0.01.

(Fig. 3, G–I). This finding provides definitive evidence that
the failure of MHCII K–deficient DCs to effectively engage
and activate thymocytes was because of the presence of too
many MHCII molecules and not the absence of ubiquitinated MHCII in the cells.
MHCII K deficiency alters the lipid raft
and tetraspanin web in the plasma
membrane of DCs

We sought to identify the specific mechanism by which too
many MHCII molecules impair DC ability to engage and activate thymocytes. MHCII is not randomly scattered in the
plasma membrane of DCs but is associated with a distinct
membrane domain named lipid raft, an ordered membrane
structure composed of discrete species of lipids, including
cholesterol, sphingolipid, and glycolipid (Anderson et al.,
2000; Anderson and Roche, 2015). The lipid raft also encompasses a specific set of proteins including glycosylphosphatidylinositol (GPI)-anchored molecules (Simons and Sampaio,
2011). Although the mechanism by which MHCII associates
with the lipid raft is not clearly understood, this association increases the local concentration of MHCII loaded with antigens
lowering the threshold of antigen-specific T cell activation
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Figure 4. MHCII K deficiency causes DCs to
be poorly bound by antibodies or ligand directed to the molecules associated with the
lipid raft and tetraspanin web. (A and B)
BMDCs derived from WT or MHCIIK>R/K>R mice
were stained by using monoclonal antibodies
raised against indicated molecules except that
CTxB was used to detect GM1. Note that two
monoclonal antibodies (MZ3 and KMC8) were
used for CD9. Isotype control antibodies or
unstained cells (for CTxB) were used as background (gray). Sirpα− DCs are shown as the
representative of BMDCs. (C and D) BMDCs
derived from WT or MHCIIK>R/K>R mice were
fixed with paraformaldehyde. Some were subsequently permeabilized and some were not
before staining with antibodies or CTxB as
described in A and B. Sirpα− DCs are shown
as the representative. (E) BMDCs derived from
WT or MHC
IIK>R/K>R mice were lysed with
TRIzol, and the amount of mRNA of indicated
molecules was determined by quantitative RTPCR. Data were normalized to mRNA of HPRT.
Error bars represent SEM. (F) BMDCs derived
from WT or MHC
IIK>R/K>R mice were run on
SDS-PAGE and probed by using antibodies
raised against indicated molecules. Data represent two to four independent experiments.

(Anderson et al., 2000). We found that MHCII in MHCII K–
deficient DCs was fractionated into the light-buoyant density fractions at degrees similar to MHCII in WT DCs (Fig.
S3), indicating that ubiquitination is not required for MHC
II to associate with the lipid raft. However, we noticed that
the absolute amount of MHCII associated with the lipid raft
was markedly high in MHCII K–deficient DCs, although the
amount associated with nonlipid raft was also high (Fig. S3).
Because the lipid raft is an ordered structure made by tight
interactions between lipids and proteins, we speculated that
excessive accumulation of MHCII in the lipid raft might have
altered the integrity of the structure, which in turn negatively
affected the ability of MHCII K–deficient DCs to engage and
activate thymocytes. Interestingly, we found that the antibodies raised against the GPI-anchored molecule CD48 or CD24
poorly bound to MHCII K–deficient DCs compared with WT
DCs (Fig. 4 A). Cholera toxin B (CTxB), a specific ligand
of the sphingolipid GM1, also poorly bound to MHCII K–
deficient DCs (Fig. 4 A). However, the antibodies raised
against the nonraft molecules CD45 and CD71 bound to MHC
II K–deficient DCs similarly to WT DCs (Fig. 4 A).
In addition to the lipid raft, another membrane domain
named tetraspanin web associates MHCII in DCs (Kropshofer
Role of MARCH1 in plasma membrane homeostasis • Oh et al.
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MHCII overcrowding is responsible for the
alteration of the lipid raft and tetraspanin
web in MHCII K–deficient DCs

Next, we determined whether the alteration of the lipid raft and
tetraspanin web in MHCII K–deficient DCs was caused by MHC
II overcrowding. DCs were cultured from MHCIIK>R/− mice and
examined whether these DCs are better bound by anti-CD48,
-CD24, or -CD9 antibodies and CTxB than DCs derived from
MHCIIK>R/K>R mice. We found that all of these antibodies and
CTxB bound better to DCs derived from MHCIIK>R/− mice
(Fig. 5 A). We also examined binding of these antibodies and
CTxB to DCs that expressed the MHCII (K>R) mutant and WT
under the retroviral promoter described in Fig. 3. All the antibodies and CTxB bound to DCs that expressed MHCII WT or
the MHCII (K>R) mutant at similar levels (Fig. 5 B). These
findings strongly support the hypothesis MHCII overcrowding
is responsible for the alteration of the lipid raft and tetraspanin
web in MHCII K–deficient DCs.
To further confirm that the alteration of the lipid raft and
tetraspanin web in MHCII K–deficient DCs is attributed directly
to MHCII overcrowding, we ablated MHCII ubiquitination in
DCs in an inducible manner. The MARCH1fl/fl mice described
in Fig. 1 were crossed with ERT-Cre mice, which expressed estrogen receptor–Cre fusion protein under the human ubiquitin
promoter. BMDCs were cultured from these mice and treated
with the ligand of the estrogen receptor tamoxifen. Tamoxifen
was expected to enter DCs and trigger cre-dependent recombination of the MARCH1 gene. We found that tamoxifen treatment resulted in an increase in the surface level of MHCII in
as early as 24 h (Fig. 5 C). Importantly, this increase was accompanied by a reduction in the binding of anti-CD48, -CD24,
or -CD9 antibodies but not CTxB (Fig. 5 C). On day 3 to 5
after tamoxifen treatment, the level of surface MHCII further
increased whereas the binding of anti-CD48, -CD24, or -CD9
antibodies further decreased, and CTxB binding also decreased
(Fig. 5 C). These data demonstrate a strong correlation between
the degree of MHCII overcrowding and the degree of alteration of the lipid raft and tetraspanin web, further supporting
that MHCII overcrowding is the direct cause of alteration in
these membrane domains. In addition, this finding suggests that
GPI-anchored molecules and tetraspanin molecules are more
readily altered than GM1 by MHCII overcrowding.
Because MARCH1 ablation increases not only MHCII
but also CD86, we tested whether CD86 accumulation may also
induce similar alteration in the lipid raft and tetraspanin web.
DCs derived from WT mice were transduced with the retrovirus encoding CD86 (K>R) mutant in which the cytoplasmic
lysines of CD86 were replaced with arginines (Baravalle et al.,
2011). We found that the cells transduced with this retrovirus
expressed >50 times as many CD86 molecules as untransduced
cells. However, the transduced and untransduced cells were
bound by anti-CD24, -CD48, or -CD9 antibody and CTxB similarly (Fig. S4), indicating that CD86 overcrowding does not
make an alteration similar to what MHCII overcrowding makes.
Lipid raft and tetraspanin web support DC
engagement and activation of thymocytes

We examined whether intact lipid raft or tetraspanin web is
required for DCs to stably engage and sufficiently activate
thymocytes. First, we disturbed the organization of these membrane domains by using methyl β-cyclodextrin (MβCD), a
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et al., 2002; Unternaehrer et al., 2007). This membrane domain consists of tetraspanin molecules and a limited number
of partner proteins and is enriched with cholesterol and the
sphingolipid ganglioside similarly to the lipid raft (Charrin et
al., 2014). We found that the antibodies raised against the tetraspanin molecule CD9 or CD81 also poorly bound to MHCII
K–deficient DCs compared with WT DCs (Fig. 4 B). Antibodies raised against CD63, CD37, or CD54 did not bind to either
WT or MHCII K–deficient DCs possibly by little expression of
these tetraspanins in the DC surface (unpublished data). These
findings suggest that MHCII K deficiency induces substantial
alteration in the composition or structure of the lipid raft and
tetraspanin web in DC plasma membrane.
To better characterize alteration of the lipid raft and tetraspanin web in MHCII K–deficient DCs, we examined whether
the alteration was restricted to the plasma membrane or also
made in the intracellular compartments. First, we examined
whether the aforementioned antibodies or CTxB bind more
poorly to MHCII K–deficient DCs than WT DCs after fixation. As shown in Fig. 4 C. the antibodies and CTxB poorly
bound to fixed MHCII (K>R) DCs compared with fixed WT
DCs. Then, we permeabilized the fixed DCs and stained them
with the antibodies and CTxB. Permeabilization substantially
increased the binding of anti-CD48 antibody, anti-CD24 antibody, and CTxB, implicating the presence of these molecules
in intracellular compartments (Fig. 4 C). Notably, we found that
permeabilization markedly reduced the difference in binding of
the antibodies or CTxB between MHCII K–deficient DCs and
WT DCs (Fig. 4 C), suggesting that the lipid raft in the intracellular compartments of MHCII K–deficient DCs is not altered as
much as that in the plasma membrane.
CD9 appeared mostly localized in the plasma membrane
in DCs because permeabilization increased anti-CD9 antibody binding only to a marginal level (Fig. 4 C). The difference in binding of anti-CD9 antibody between WT and MHC
II K–deficient DCs did not look much different after permeabilization. Binding of anti-CD81 antibody was substantially
increased after permeabilization, implicating the presence of
a substantial amount of intracellular CD81 (Fig. 4 D). The
degree of binding difference between WT and MHCII K–deficient DCs also increased after permeabilization indicating
that there might be substantial alteration in CD81-associating
tetraspanin web in the intracellular compartments of MHCII
K-deficient DCs (Fig. 4 D).
Next, we examined whether MHCII K–deficient DCs expressed lipid raft or tetraspanin molecules at lower levels than
WT DCs. First, we determined the level of mRNA by quantitative RT-PCR. We did not find any significant reduction in the
amount of transcript of CD48, CD24, CD9, or Sptlc2, the key
enzyme in sphingolipid biosynthesis, in MHCII K–deficient
DCs compared with WT DCs (Fig. 4 E). Second, we examined
the protein amount by Western blot analysis. No difference was
observed in the amount of CD48, CD9, or CD81, although the
amount of CD24 appeared slightly lower in MHCII K–deficient
DCs (Fig. 4 F). Thus, MHCII K–deficient DCs express CD48,
CD9, and CD81 at levels similar to WT DCs whereas CD24
might be expressed at slightly lower levels. Collectively, we
conclude that that MHCII K deficiency in DCs is accompanied
by substantial changes in the conformation and stability of the
molecules associated with the lipid raft and tetraspanin web
in the plasma membrane.

Figure 5. MHCII overcrowding is responsible
for alteration of the lipid raft and tetraspanin
web in MHC
II K–deficient DCs. (A) BMDCs
derived from WT, MHC
IIK>R/K>R, or MHC
II
K>R/- mice were stained by using monoclonal
antibodies raised against indicated molecules
except that CTxB was used to detect GM1.
Sirpα− DCs are shown as the representative.
(B) BMDCs derived from MHC
IIβ−/− mice
and subsequently transduced with retrovirus
encoding MHCII WT or MHCII (K>R) mutant
were treated and analyzed as described in
A. Sirpα− DCs are shown as the representative. (C) BMDCs cultured from MARCH1fl/flERTCre mice were treated with tamoxifen. On
days 0, 1, 3, and 5 posttreatment, cells were
stained with CTxB (to detect GM1) or antibodies raised against CD48, CD24, CD9,
or MHC
II. Sirpα− DCs are shown as the
representative. Data represent two to four
independent experiments.
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cholesterol-chelating agent (Charrin et al., 2003). MβCD treatment diminished DC binding by anti-CD48, -CD24, or -CD9
antibodies, and CTxB (Fig. 6 A), similarly to what MHCII K
deficiency did. MβCD treatment also impaired DC ability to engage and activate thymocytes (Fig. 6, B–D). Next, we treated
BMDCs with myriocin, a potent and specific inhibitor of sptlc2
(Hanada, 2003). Myriocin did not impair DC binding by antiCD48 or -CD24 antibodies although it modestly impaired binding by CTxB and anti-CD9 or -CD81 antibodies (Fig. 6 E).
Myriocin treatment significantly reduced the efficiency of DCs
to engage and activate thymocytes (Fig. 6, F–H). Notably however, myriocin treatment markedly reduced the surface expression of MHCII in DCs (unpublished data). Because surface
MHCII makes a direct impact on the efficiency of DC activation of antigen-specific thymocytes, it is unclear whether the
reduced engagement and activation of thymocytes by myriocin-treated DCs is the result of the perturbation of the lipid raft
or tetraspanin web or the reduced surface expression of MHCII.
Then, we examined whether any specific molecules associated with the lipid raft or tetraspanin web are important for
DCs to stably engage and sufficiently activate thymocytes. To
this end, we pretreated DCs with anti-CD48, -CD24, -CD9,
or -CD81 antibodies before culturing with OT-II thymocytes.
We found that all of the antibodies appreciably reduced DC engagement with thymocytes compared with the control antibody
(anti-TNP), although the statistically significant difference was
reached only by anti-CD48 antibody and the KMC8 anti-CD9
antibody. (Fig. 6 I). These two antibodies also reduced DC
engagement and activation of thymocytes at significant levels
(Fig. 6, J and K). This finding implicates the role of CD48 and
CD9 in DC engagement and activation of thymocytes and sug-

gests that alteration of these two molecules may be the primary
cause for diminished engagement and activation of thymocytes
by MHCII K–deficient DCs.
Sphingomyelin supplementation lessens the
alteration of the lipid raft and tetraspanin
web in MHCII K–deficient DCs and improves
the ability of the DCs to engage and activate
thymocytes and drive Treg cell differentiation

We sought to determine the specific mechanism by which MHC
II overcrowding alters the lipid raft or tetraspanin web and determine whether this alteration is responsible for poor engagement
and activation of thymocytes by MHCII K–deficient DCs. It has
been suggested that MHCII binds cholesterol and sphingolipid
through its transmembrane domain (Roy et al., 2013; Björkholm
et al., 2014). We postulated that cholesterol and sphingolipid in
the lipid raft and tetraspanin web may be sequestered by MHCII
because MHCII accumulates in these membrane domains. This
sequestration would make other molecules associated with the
lipid raft or tetraspanin web deprived of cholesterol or sphingolipid, resulting in alteration in the conformation or stability of
the molecules. To test this hypothesis, we supplemented MHC
II K–deficient DC culture with cholesterol or sphingomyelin
and examined whether this supplementation makes the DCs
better bound by anti-CD48, -CD24, -CD9, or -CD81 antibodies or CTxB. We found that sphingomyelin significantly improved DC binding by all these reagents (Fig. 7 A) although
cholesterol did not (not depicted). Importantly, sphingomyelin
also significantly improved the ability of MHCII K–deficient
DCs to engage and activate thymocytes (Fig. 7, B–D). Then,
we examined whether sphingomyelin treatment also improves
Role of MARCH1 in plasma membrane homeostasis • Oh et al.
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Figure 6. Lipid raft and tetraspanin web support DC engagement and activation of thymocytes. (A) BMDCs were treated with PBS or MβCD (4 mM) for
3 h and stained by using monoclonal antibodies raised against indicated molecules except that CTxB was used to detect GM1. (B–D) BMDCs pretreated
with PBS or MβCD were cultured with CD4+CD8− thymocytes isolated from OT-II mice in the presence of increasing concentrations of OVA323-339 peptide.
The percentage of DCs that formed stable conjugates with thymocytes is shown in B. The percentage of thymocytes that expressed CD69 is shown in
C. The level of CD25 expressed in CD69+ thymocytes is shown in D. (E) BMDCs were treated with methanol (MeOH) or myriocin (0.5 μg/ml) for 3 d and
stained by using monoclonal antibodies raised against indicated molecules except that CTxB was used to detect GM1. (F–H) BMDCs treated with MeOH
or myriocin were cultured with CD4+CD8− thymocytes isolated from OT-II mice in the presence of increasing concentrations of OVA323-339 peptide. The
percentage of DCs that formed stable conjugates with thymocytes is shown in F. The percentage of thymocytes that expressed CD69 is shown in G. The
level of CD25 expressed in CD69+ thymocytes is shown in H. (I–K) BMDCs were treated with indicated antibodies for 30 min at 37°C. After washing, the
DCs were cultured with CD4+CD8− thymocytes isolated from OT-II mice in the presence of increasing concentrations of OVA323-339 peptide. The percentage
of DCs that formed stable conjugates with thymocytes is shown in I. The percentage of thymocytes that expressed CD69 is shown in J. The level of CD25
expressed in CD69+ thymocytes is shown in K. Statistical analysis was performed in comparison to the cells treated with anti-TNP antibody (control) in
I–K. Data represent three to four independent experiments. Error bar represents SEM. *, P < 0.05; **, P < 0.01.

the ability of MHCII K–deficient DCs to drive Treg cell development. Immature non-Treg CD4+ thymocytes were isolated
from FoxpGFPOT-II mice, which report Foxp3 by GFP expression. The isolated thymocytes were co-cultured with MHCII K–
deficient DCs that had been supplemented with sphingomyelin
in the presence of increasing concentrations of ovalbumin peptide. 2 d later, the expression of GFP and CD25 in thymocytes
was determined by flow cytometry. We found that the thymo8
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cytes cultured with sphingomyelin-treated DCs expressed GFP
and CD25, the markers of Treg cells, at a significantly higher
frequency than those cultured with vehicle-treated DCs (Fig. 7,
E and F). Thus, sphingomyelin supplementation significantly
restores the ability of MHCII K–deficient DCs to drive Treg
cell development. Collectively, these findings suggest that the
alteration of the lipid raft and tetraspanin web was responsible
for poor engagement, activation, and Treg cell differentiation
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Figure 7. Sphingomyelin supplementation lessens alteration of the lipid raft and tetraspanin web in MHCII K–deficient DCs and improves the ability of the
DCs to engage and activate thymocytes and drive Treg cell differentiation. (A) BMDCs were derived from MHCIIK>R/K>R mice, treated with ethanol (EtOH) or
sphingomyelin (SM; 200 µM) for 3 d and stained by using monoclonal antibodies raised against indicated molecules except that CTxB was used to detect
GM1. (B–D) BMDCs derived from MHCIIK>R/K>R mice were treated with EtOH or SM and cultured with CD4+CD8− thymocytes isolated from OT-II mice in
the presence of increasing concentrations of OVA323-339 peptide. The percentage of DCs that formed stable conjugates with thymocytes is shown in B. The
percentage of thymocytes that expressed CD69 is shown in C. The level of CD25 expressed in CD69+ thymocytes is shown in D. (E and F) BMDCs derived
from MHCIIK>R/K>R mice were treated with EtOH or SM and cultured with GFP−CD4+CD8− thymocytes isolated from Foxp3GFPOT-II mice in the presence of
increasing concentrations of OVA323-339 peptide. 2 d later, the expression of GFP and CD25 in the thymocytes was determined by flow cytometry. Representative dot plots are shown in E. The percentage of GFP+CD25+ cells among thymocytes (Treg cells) is shown in F. Data represent two to four independent
experiments. Error bars represent SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.005.

of thymocytes by MHCII K–deficient DCs and suggest that
sphingolipid may be one of the limiting factors in MHCII K–
deficient DCs for maintaining homeostasis of the lipid raft and
tetraspanin web against MHCII overcrowding.
The degree of Treg cell deficiency in MAR
CH1- or MHCII K–deficient mice correlates
with the degree of alteration in the lipid
raft and tetraspanin web in thymic DCs

The data described so far led to the hypothesis that the failure
of MHCIIK>R/K>R or MARCH1−/− mice to generate Treg cells to
a sufficient number is attributed to the failure of thymic DCs
of these mice to maintain homeostasis of the lipid raft and/or
tetraspanin web. To test this hypothesis, we first examined thymic DCs derived from WT, MHCIIK>R/K>R, and MHCIIK>R/− for
binding by anti-CD48, -CD24, or -CD9 antibodies and CTxB.
Similar to what was observed with BMDCs (Fig. 5 A), these
antibodies and reagent bound to DCs derived from WT mice
the most, and DCs derived from MHCIIK>R/K>R mice the least
(Fig. 8 A). Then, we compared the ability of these mice to
generate antigen-specific Treg cells. The generation of OVAspecific Treg cells was examined in conditions where OVA was

expressed in the thymus under the control of a rat insulin promoter (Fig. 8 B) or administered to the circulation (Fig. 8 C;
Oh et al., 2013). Although MHCIIK>R/K>R mice completely failed
to generate OVA-specific Treg cells in both conditions, MHC
IIK>R/− mice generated them to an appreciable amount; however,
it did not reach the amount generated by WT mice (Fig. 8, B and
C). Lastly, we compared the amount of total Treg cells in WT,
MHCIIK>R/K>R, and MHCIIK>R/− mice. Treg cell frequency was
reduced by half in MHCIIK>R/K>R mice compared with WT mice,
and it remained similarly low in MHCIIK>R/− mice (Fig. 8 D).
We performed similar experiments using MARCH1−/−
and MARCH1−/+ mice. Thymic DCs of MARCH1−/− mice were
most poorly bound by anti-CD48, -CD24, or -CD9 antibodies
and CTxB, and DCs of MARCH1−/= mice showed markedly
improved binding (Fig. 8 E). OVA-specific Treg cells were not
generated at all in MARCH1−/− mice but were generated in MAR
CH1−/+ mice as efficiently as in WT mice both when OVA was
expressed in the thymus and when administered to the circulation (Fig. 8, F and G). The total Treg cell amount was also
significantly restored in MARCH1−/+ mice, although it did not
reach the level of WT mice (Fig. 8 H). Collectively, Treg development in the thymus decreased in proportion to the degree to
Role of MARCH1 in plasma membrane homeostasis • Oh et al.
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which the lipid raft and tetraspanin web were altered in thymic
DCs. These data suggest the important contribution of the DC
lipid raft and tetraspanin web to Treg cell development.
MARCH1 significantly contributes to
the diversification of Treg cell repertoire
and function

Having found the mechanism by which MARCH1 supports DC
selection of Treg cells, we explored the functional significance
of this mechanism. Specifically, we determined the contribution that MARCH1 may make to the diversity of Treg cells.
MARCH1−/− mice were crossed to transgenic mice with a fixed
TCRβ chain (Hsieh et al., 2004). Treg cells were isolated, and
the variable TCRα chains were sequenced and analyzed at the
individual TCR level (Fig. S5, A and B). We found a substantial loss of Treg cell TCR clones in MARCH1-deficient mice,
estimated to comprise ∼33% of the Treg cell TCR clones
present in WT mice (Fig. 9, A and B). Remarkably, most of
them completely disappeared in MARCH1−/− mice (Fig. 9 A).
Some clones were found enriched, although the frequency was
as low as 2.3% (Fig. 9, A and B). This finding indicates that
MARCH1 plays a significant role in diversifying Treg cell TCR
repertoire. We also examined the TCR repertoire of non-Treg
CD4+ thymocytes and found that 8.4% of the analyzed TCRs
were enriched in MARCH1−/− mice (Figs. S5, C and D). Thus,
10
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MARCH1 appears to also play some role in negatively selecting CD4+ thymocytes.
Next, we examined whether the restriction in the repertoire
of Treg cells in MARCH1-deficient mice is accompanied by the
restriction in their functional capacity. Treg cells isolated from
MARCH1-deficient mice suppressed proliferation of CD4+ T
cells as effectively as those from WT mice in vitro (Fig. 9 C). To
assess Treg cell functionality in physiologically relevant settings,
we used two in vivo assays. First, we transferred naive CD4+ T
cells to lymphopenic mice (Powrie et al., 1994), which develop
wasting disease and inflammatory bowel disease (IBD), which
are ameliorated by cotransfer of Treg cells (Mottet et al., 2003).
We found that Treg cells derived form MARCH1-deficient mice
suppressed both wasting disease and IBD as well as or more
effectively than those from WT mice (Fig. 9 D and Fig. S5 E).
Second, we used a mouse model of lethal acute graft-versus-host
disease (aGVHD) preventable by cotransfer of Treg cells derived
from the graft donor (Hoffmann et al., 2002). Transplantation of
irradiated BALB/c mice with C57BL/6 mouse bone marrow cells
that included CD4+ T cells but not Treg cells resulted in a precipitous death leaving no mice surviving on day 22 after transplantation (Fig. 9 E). However, mice cotransplanted with Treg cells
derived from WT C57BL/6 mice were substantially protected
from death, resulting in about two thirds of the mice surviving over 36 d after transplantation (Fig. 9 E). In contrast, mice
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Figure 8. The degree of Treg cell deficiency in
MARCH1 or MHCII K–deficient mice correlates
with the degree of alteration in the lipid raft
and tetraspanin web in thymic DCs. (A) DCs
were enriched from the thymic digest of WT,
MHCIIK>R/K>R, and MHCIIK>R/- mice and stained
by using monoclonal antibodies raised against
indicated molecules except that CTxB was
used to detect GM1. Sirpα− DCs are shown
as the representative. Data represent at least
three independent experiments. (B) WT (−) and
Rip-mOVA (+) transgenic mice were lethally
irradiated and transferred with bone marrow
isolated from OT-II, MHCIIK>R/K>ROT-II, or MHC
IIK>R/-OT-II mice. The percentage of OT-II Treg
cells among CD4+ thymocytes was determined 6 wk later. (C) OT-II, MHCIIK>R/K>ROT-II,
and MHCIIK>R/-OT-II mice were i.v. injected
with PBS (−) or 4 mg ovalbumin (+), and
the percentage of OT-II Treg cells among
CD4+ thymocytes was determined 3 d later.
(D) The percentage of Treg cells among CD4+
thymocytes in WT, MHC
IIK>R/K>R, and MHC
IIK>R/- mice. (E) DCs were enriched from the
thymic digest of WT, MARCH1−/−, and MAR
CH1−/+ mice and stained by using monoclonal
antibodies raised against indicated molecules
except that CTxB was used to detect GM1.
Sirpα− DCs are shown as the representative.
Data represent at least three independent experiments. (F) Mice were treated as described in
B, except that bone marrow was isolated from
OT-II, MARCH1−/−OT-II, and MARCH1−/+OT-II
mice. (G) Mice were treated as described in
C, except that OT-II, MAR
CH1−/−OT-II, and
MARCH1−/+OT-II mice were i.v. injected with
PBS (−) or ovalbumin (+). (H) The percentage
of Treg cells among CD4+ thymocytes in WT,
MARCH1−/−, and MAR
CH1−/+ mice. Each
circle represents an individual mouse. Data
were pooled from more than three independent experiments. Error bars represent SEM.
*, P < 0.05; **, P < 0.01.
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Figure 9. MARCH1 significantly contributes to the diversification of Treg cell repertoire and function. (A) Dot plot of unique Treg cell TCR frequencies in
MARCH1−/− versus WT mice. Red and blue dots indicate unique TCRs significantly diminished and enriched in MARCH1−/− mice, respectively (P < 0.075,
Mann-Whitney U test). ND, not detected. (B) The percentages of unique Treg cell TCR clones diminished or enriched significantly and more than fivefold in
MARCH1−/− mice. (C) Treg cells were isolated from thymi of WT or MARCH1−/− mice and mixed with CTV-labeled CD4+ T cells together with anti-CD3 and
-CD28 antibody–coated beads. The percentages of CTV-diluted CD4+ T cells were determined. Data represent two independent experiments with triplicates
per condition. Error bars represent SEM. (D and E) RAG1−/− mice were i.v. injected with naive WT CD4+ T cells alone or together with thymic Treg cells
isolated from WT or MARCH1−/− mice. The weight of individual mice was monitored and recorded for 56 d (D). Each curve represents the average weight
changes of 12–13 mice per group. Histological scores of distal colons were determined as described in Materials and methods (E). Each circle represents
an individual mouse. Data are pooled from three independent experiments. Error bars represent SEM. *, P < 0.05; **, P < 0.01. (F) BALB/c mice were
lethally irradiated and i.v. injected with C57BL/6 mouse bone marrow cells depleted of whole T cells and supplemented with C57BL/6 mouse CD4+ T cells
alone or together with thymic Treg cells isolated from WT or MARCH1−/− mice. Survival of the mice was monitored for 36 d. Data were pooled from three
independent experiments of 10–15 mice per group. Significance was tested by the log-rank test. *, P < 0.05.

cotransplanted with Treg cells derived from MARCH1-deficient
C57BL/6 mice died as rapidly as those transplanted with CD4+ T
cells alone, although some mice managed to live (Fig. 9 E). Thus,
Treg cells generated in the absence of MARCH1 are incompetent
in suppressing lethal aGVHD. These findings suggest that MAR
CH1 contributes to the diversification of the immunosuppressive
function of Treg cells as well as TCR repertoire of the cells.

Discussion
The aim of this study was to define the mechanism by which
MAR
CH1-mediated ubiquitination of MHC
II supports DC

function of selecting natural Treg cells. The presented study
indicates that ubiquitin-dependent MHCII turnover is required
for DCs to maintain homeostasis of the lipid raft and tetraspanin
web in the plasma membrane and that DC ability to engage and
activate thymocytes is critically dependent on integrity of these
membrane domains. Thus, MARCH1-mediatd MHCII ubiquitination represents a novel quality-control mechanism by which
DCs maintain homeostasis of membrane domains that supports
Treg cell–selecting function.
Ubiquitination induces endocytosis and lysosomal sorting
and degradation of MHCII. Accordingly, when the ubiquitin acceptor lysine of MHCII was mutated in mice, the level of MHC
II molecules, including the antigen-loaded MHCII, markedly
Role of MARCH1 in plasma membrane homeostasis • Oh et al.

11

12

JCB

• 2018

cytes remain to be further defined. We found that pretreatment
with anti-CD48 antibody resulted in a significant reduction in
DC ability to engage and activate thymocytes, implicating a role
of CD48. CD48 has been shown to bind the adhesion molecule
CD2 and facilitate activation of T cells (Kato et al., 1992). A
similar mechanism may explain the contribution of CD48 to
DC engagement and activation of thymocytes. Pretreatment
of DCs with anti-CD9 antibody also resulted in a reduction in
DC engagement and activation of thymocytes, although only
the KMC8 antibody but not the MZ3 antibody did so. Although
the specific epitope recognized by the KMC8 antibody is not
known, that epitope may mediate CD9 interaction with some
other molecules that promote DC engagement and activation of
thymocytes. CD9 and CD81 can interact with multiple integrin
molecules in the plasma membrane through their ectodomains
(Berditchevski, 2001). CD9 and CD81 are also connected
to actin cytoskeleton involving ezrin-radixin-moesin proteins
(Sala-Valdés et al., 2006). Thus, these tetraspanin molecules
may serve as a linker between adhesion molecules on the surface of DCs and the cytoskeleton in the cortex and promote
stable DC interaction with thymocytes. The co-stimulatory
molecule CD86 has been shown to be recruited to the lipid raft
upon T cell–DC interaction, implicating the role of the lipid
raft in T cell stimulatory activity of CD86. Although we did not
examine it in this study, MHCII K deficiency may have caused
CD86 to poorly associate with the lipid raft in MHCII (K>R)
DCs making it unable to provide sufficient co-stimulatory signal to the interacting thymocytes.
We found that MARCH1 deficiency reduced not only the
number of Treg cells but also repertoire of the cells. Approximately 33% of Treg TCR clones diminished in MARCH1deficient mice, and the majority of them were undetectable. We
also found some clones of non-Treg CD4+ thymocytes were
enriched in MARCH1-deficient mice. However, the frequency
of these enriched clones comprised only 8% of total non-Treg
CD4+ thymocyte repertoire, implicating a relatively minor role of
MARCH1 in negative selection over Treg cell development. Both
negative selection and Treg cell development are promoted by
high-affinity interaction between DCs and thymocytes. However,
a recent study has revealed that the TCR affinity threshold to
elicit negative selection is ∼100-fold higher than that of Treg cell
development. This study also showed that Treg cells can develop
in a broad ∼1,000-fold range of TCR affinity. This extremely
broad range of Treg cell affinity may be attributed to the role of
the lipid raft and tetraspanin web in promoting DC engagement
and activation of thymocytes. We found that the Treg cells generated in the absence of MARCH1 sufficiently suppressed wasting
disease and IBD but not aGVHD. Previous studies have shown
that the alloantigen-specific Treg cells suppressed alloreactive
effector T cells more effectively than polyclonal Treg cells in
vitro (Chen et al., 2009; Veerapathran et al., 2013). Alloantigenspecific Treg cells also suppressed aGVHD more effectively than
polyclonal Treg cells when transferred to mice that received allotransplantation (Yamazaki et al., 2006; Golshayan et al., 2007).
Thus, MARCH1 may play a particularly important role in the
development of Treg cells reactive to alloantigens.
In conclusion, this study reveals an unexpected role of
MARCH1 and MHCII ubiquitination in DC membrane homeostasis and Treg cell–selecting function. The dependency
of MARCH1 and MHCII ubiquitination in other DC functions,
such as development of effector T cells, would be an important
remaining topic to be studied.
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increased in DC surface. Yet, the DCs were less efficient at activating antigen-specific thymocytes than WT DCs. By using two
independent methods, we showed that this reduced efficiency is
attributed not to the absence of ubiquitinated MHCII molecules
in the cells but to the presence of too many MHCII molecules.
First, we found that the efficiency of MHCII K–deficient DCs
at engaging and activating thymocytes was significantly improved when the cells were manipulated to express only one
allele of the MHCII. Second, DCs that expressed MHCII via an
exogenous promoter that drove MHCII expression much more
weakly compared with the endogenous promoter were able to
stably engage and strongly activate thymocytes in the absence
of the ubiquitin acceptor lysine in MHCII.
We found that MHCII K deficiency resulted in distortion
of the lipid raft and tetraspanin web in the plasma membrane
of DCs. This distortion was manifested by poor binding of the
antibodies or ligands directed to GPI-anchored molecules, GM1,
or tetraspanin molecules. This poor binding appears to be largely
attributed to conformational changes of the individual molecules
driven by MHCII overcrowding in the membrane domains. A
recent study has shown that the fraction of GM1 molecules
available for CTxB binding changes as the property of GM1associating membrane changes (Sachl et al., 2015). Another recent study has shown that tetraspanin molecules contain a large
intramembrane cavity occupied by cholesterol and that the occupancy of this cavity modulates conformation of tetraspanins
(Zimmerman et al., 2016). Possibly, the lipid raft and tetraspanin
web in MHCII K–deficient DCs were altered in membrane property by MHCII overcrowding, which resulted in conformational
changes in the associated molecules including GM1. Notably, we found that the amount of CD24 present in MHCII K–
deficient DCs was slightly lower than that in WT DCs, although
the amount of CD24 transcript was identical. We speculate that
some of the CD24 molecules in MHCII K–deficient DCs might
have been cleaved from the cell surface because phosphatidylinositol-phospholipase C and the angiotensin-converting enzyme, the enzymes capable of cleaving GPI anchor, are activated
upon destabilization of the lipid raft (Metz et al., 1994; Sharom
and Lehto, 2002; Kondoh et al., 2005). Additional studies using
high-resolution microscopy and biophysical experiments would
help in understanding the molecular changes occurring in the
plasma membrane of MHCII-overcrowded DCs.
The lipid raft and tetraspanin web both promote DC activity of engaging and activating mature CD4+ T cells (Anderson et al., 2000; Kropshofer et al., 2002; Hiltbold et al., 2003).
However, the role of these membrane domains in DC activity of
engaging, activating, and differentiating CD4+ thymocytes has
not been investigated. Cholesterol and sphingolipid both play
an important role in maintaining structural integrity of the lipid
raft as well as the tetraspanin web (Odintsova et al., 2006). We
found that DCs treated with the reagents that reduce cellular
levels of cholesterol or sphingolipid were poorly bound by the
antibodies or ligand directed to the molecules associated with
the lipid raft or tetraspanin web, similarly to what was found
in MHCII K–deficient DCs. DCs treated with these reagents
also poorly engaged and activated thymocytes compared with
untreated DCs. This finding supports that the lipid raft and tetraspanin web were disrupted in MHCII K–deficient DCs and
that these membrane domains play an important role in DCs to
stably engage and strongly activate thymocytes.
The specific mechanisms by which the lipid raft or tetraspanin web supports DC ability to conjugate and activate thymo-

Materials and methods
Mice

C57BL/6, BALB/c, B6.PL-Thy1a/CyJ (Thy1.1), B6.129S2-H2dlAb1-Ea/J
(MHCII−/−), B6.129S2-Tcratm1Mom/J (TCRα−/−), B6.129S7-Rag1tm/1Mom/J
(Rag1−/−), B6.Cg-Tg(Itgax-cre)1-1Reiz/J (CD11c-CRE), B6.CgTg(UBC-cre/ERT2)1Ejb (ERT-CRE), B6;SJL-Tg(ACT
FLPe)9205Dym/J (ACT-FLP), B6.Cg-Tg(TcraTcrb)425Cbn/J (OT-II), and
B6.SJL-Ptprca Pepcb/BoyJ (BoyJ) mice were purchased from the Jackson Laboratory. B6.129-H20Ab1tm1GruN12 (MHCIIβ−/−) mice were
purchased from Taconic. MHCIIK>R/K>R (Oh et al., 2013), MARCH1−/−
(Matsuki et al., 2007), Rip-mOVA (Kurts et al., 1996), foxp3GFP
(Haribhai et al., 2007), and TCli β transgenic (Hsieh et al., 2004) mice
were described previously. All mice were maintained in the University
of California, San Francisco (UCSF), mouse facility, and all animal
studies were performed according to protocols approved by the UCSF
Institutional Animal Ethics Committee.

Culture of BMDCs and isolation of conventional DCs (cDCs)

Bone marrow cells were cultured with RPMI media supplemented with
10% FBS and 100 ng/ml Flt3-ligand (Peprotech) for 12 d. For isolation of cDCs, cells were harvested and preincubated with Fc block for
10 min on ice in MACS buffer (PBS with 1% BSA and 2 mM EDTA)
and then with biotin-B220 antibody and streptavidin–magnetic bead
to remove plasmacytoid DCs. These cDCs were further purified by
cell sorting before RNA isolation, Western blotting, and sucrose
gradient fractionation.
Retroviral transduction of BMDCs

The retrovirus encoding MHCII WT, MHCII (K>R) mutant, or CD86
(K>R) mutant was generated as previously described (Shin et al., 2006;
Baravalle et al., 2011). The generated virus was mixed with polybrene
(10 µg/ml) and added to BMDCs on the second day of culture. The
BMDCs were spun at 2,500 rpm for 2 h at RT, and the supernatant was
replaced with the Flt3-ligand-containing media. Cells were cultured for
an additional 10 to 12 d.

Antibodies and reagents

Generation of MARCH1fl/flCD11c-CRE mice

Embryonic stem cells containing targeted conditional alleles of
MAR
CH1 were purchased from EUC
OMM and transplanted to
C57BL/6 mice in the UC Davis Mouse Biology Program. Two chimeric mice were generated, and both mice successfully provided
germ-line transmission. One of them was crossed with Act-FLP transgenic mice to remove the FRT flanking region and subsequently with
CD11c-CRE or ERT-Cre transgenic mice to remove the loxP-flanking region. See Fig. S1.
Isolation of thymic DCs

Thymi were isolated and digested with 125 mg/ml collagenase D
and 62.5 µg/ml DNaseI for 20 min with gentle rocking at 37°C. Digests were filtered through a 70-µm filter cap strainer (BD Falcon),
resuspended in 1 ml high-density (1.115 g/ml) Percoll solution (GE
healthcare), and layered with 1 ml low-density (1.065 g/ml) Percoll
solution followed by 1 ml PBS. This Percoll gradient was centrifuged
at 2,700 rpm for 30 min at 4°C to enrich antigen-presenting cells. Cells
between the PBS and low-density Percoll layer were isolated and used
for flow cytometric analysis as described in our previous study (Oh et
al., 2013) or enriched further by using magnetic beads conjugated with
anti-CD11c antibody (Miltenyi Biotec).

Quantitative PCR

Genomic DNA was purified using the PureLink genomic DNA
Mini kit (Invitrogen) from Sirpα− DCs (CD11c+MHCII+B220−
autofluorescence−Sirpα−), Sirpα+ DCs (CD11c+MHCII+B220−
autofluorescence−Sirpα+), B cells (B220+MHCII+CD11c−), and
thymic epithelial cells (EpCAM+MHCII+CD11c−B220−) isolated
from the thymi of MARCH1fl/fl and MARCH1fl/fl CD11c-CRE mice.
Quantitate PCR was performed on an Eppendorf realplex system by
using SYBR Green reagents and the primer pair spanning 3′ LoxP site
(5′ primer, AGCTGTAAGAACTGACCTCAA; 3′ primer, GGAGGA
TGCTTGTCCTGTAAA). See also Fig. S1. Total RNAs were isolated
from sorted cDCs by TRIzol (Invitrogen). The first-strand cDNA was
generated by using SuperScript III system (Invitrogen) with the use of
oligo dT as primer. Quantitative PCR was performed by using primers
specific for CD48, CD24, Sptlc2, CD9, and HPRT (https://pga.mgh
.harvard.edu/primerbank/).
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The following antibodies were purchased from BioLegend, eBioscience,
or BD Biosciences and used for flow cytometry or enrichment: FITCSirpα, PE/Cy7-Sirpα, PerCP/Cy5.5-B220, APC-EpCAM, PE-CD11c, PE/
Cy7-CD11c, Brilliant Violet 605-CD11c, Pacific Blue-IA/IE, FITC-CD8α,
Alexa700-CD8α, PE-Vα2, APC-Vα2, APC-Vβ5, PE-Vβ6, PE-Foxp3,
Pacific Blue-Foxp3, PerCP/Cy5.5-Thy1.1, APC-TCRβ, PE-CD69, PE/
Cy7-CD69, Brilliant Violet 605-CD4, APC-CD25, Brilliant Violet 605CD25, Brilliant Violet 785-CD25, FITC-CD45RB, APC-ICAM1, PRCD9, PE-CD81, APC-CD48, PE/Cy7-CD24, APC-CD24, PE-CD71, PE/
Cy7-CD45, APC-streptavidin, Biotin-Thy1.2, Biotin-CD8β, Biotin-CD25,
and Biotin-B220. Alexa647-CTxB subunit was purchased from Molecular
Probes. For Western blotting, the following clones were used: MHCII β
chain (Bett; homemade), CD48 (OX-78; Serotec), CD24 (M1/69; BioLegend), actin (A2066; Sigma), CD9 (LMC8; eBioscience), and CD81 (Eat2;
BioLegend), and HRP-conjugated secondary antibodies (anti-rat, antirabbit, and anti-hamster) were purchased from Jackson ImmunoResearch
or BIOSOURCE. Myriocin, MβCD, cholesterol, sphingomyelin, and 4hydroxy-tamoxifen were purchased from Sigma.

Flow cytometry and cell sorting

Cells were incubated with fluorophore-conjugated antibodies in FACS
buffer (1% BSA in PBS) containing propidium iodide solution (BioLegend) for 30 min on ice. When staining DCs, cells were preincubated
with CD16/32 Fc block antibody (UCSF Cell Culture Facility). Foxp3
was stained by using Foxp3/Transcription Factor Staining Buffer Set
as instructed (eBioscience). Samples were analyzed and sorted by the
FACS LSRII system (BD Biosciences) and BD FACS Aria3 Cell Sorter
(BD Biosciences), respectively.
Thymocyte conjugation and activation assay

CD4+ thymocytes were isolated through negative selection by using
biotin-CD8β and biotin-CD25 antibodies and streptavidin-conjugated
magnetic beads (Stemcell Technologies) from Thy1.1 OT-II mice.
Isolated cells (1 × 105) were co-cultured with thymic DCs (2 × 104)
or BMDCs (2 × 104) in the presence of increasing amounts of OVA
protein or OVA323-339 peptide. Thymocyte conjugation was assayed
after 3 h by centrifuging cell mixtures and vortexing pellets for 5 s at
the highest speed before fixation and antibody staining. The percentage of Thy1.1+Vβ5+ cells among CD11c+MHCII+ population was determined by flow cytometry. Thymocyte activation was assayed after
24 h by determining the percentages of CD69+ and the geometric mean
fluorescence intensity of CD25 of CD69+ among Thy1.1+Vβ5+ population by flow cytometry.
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Western blotting

cDCs isolated from WT and MHCIIK>R/K>R BMDCs were boiled in Laemmli buffer for 5 min and run on SDS-PAGE. Gels were transferred to
polyvinylidene difluoride membrane, and the membranes were preincubated with blocking solution (5% nonfat milk in PBST [PBS with
0.1% Tween-20]) with gentle agitation for at least 30 min, which was
followed by primary antibody incubation for overnight at 4°C and secondary antibody incubation for 1 h at RT. ECL reaction was performed,
and the membrane was imaged by using ChemiDoc XRS+ (Bio-Rad).
Sucrose gradient fractionation

BMDCs were lysed with MES-buffered saline (150 mM NaCl and
25 mM Mes, pH 6.2) containing 1% Brij-58 (Surfact-Amps 58; Thermo
Scientific) in the presence of Halt protease inhibitor Cocktail (Thermo
Scientific). The lysates were adjusted to 40% sucrose and overlaid over
a 35–5% sucrose gradient and centrifuged at 45,000 rpm for 18 h. 10
equal fractions were collected from the top of the gradient and used
for Western blot analyses.
Bone marrow transplantation

Treg cell–dependent suppression of lethal acute GVHD.

T cell–depleted C57BL/6 mouse bone marrow cells were mixed with
conventional CD4+ T cells (CD25−CD4+CD8−) isolated from C57BL/6
mouse spleens and lymph nodes. The cell mixtures were injected into
lethally irradiated (850 rad) 8- to 10-wk-old BALB/c mice (2–3 × 106
T cell–depleted bone marrow cells and 4–5 × 105 conventional CD4+ T
cells per mouse). Some mice were also injected with Treg cells isolated
from WT and MARCH1−/− mice thymi (2–2.5 × 105 cells per mouse).
Viability of mice was monitored every day for record.
Software and statistical analyses

Treg cell TCR repertoire sequencing

Treg cell and non-Treg CD4+ thymocyte TCR repertoire sequencing was performed as previously described (Perry et al., 2014).
In brief, CD4+CD8−GFP+CD25+CD24−Vβ6+Vα2+ Treg cells and
CD4+CD8−GFP−CD25−CD24−Vβ6+Vα2+ non-Treg CD4+ thymocytes
were isolated from thymi of 5- to 6-wk-old TCliβ;foxp3-EGFP;TCRα−/+
mice and MARCH1−/−;TCliβ;foxp3-EGFP;TCRα−/+ mice. cDNA was
synthesized by using a TCRα specific primer (Perry et al., 2014) and
used for amplification of the TRAV14 gene segment. The TRAV14 PCR
proceeded in two steps; the first involved the TRAV14-specific primer
(5′-GCAGCAGGTGAGACAAAG-3′) and an extension sequence (5′ACACGACGCTCTTCCGATCT-3′) with a Cα-specific reverse primer
(5′-TCAGCAGGAGGATTCGGAGTCCCA-3′). The second step used
a nested PCR with a forward primer containing the MiSeq Universal
Adapter sequence and a sequence complementary to the common extension sequence from PCR 1 with a reverse primer containing the Miseq
Universal Adapter, an 8-bp hamming code, and a sequence complementary to a portion of the Cα-specific reverse primer. Resulting amplicons were sequenced via 250-bp paired-end reads by using a MiSeq
sequencer (Illumina). Sequences were demultiplexed and analyzed using
blastn to identify the TRAV and TRAJ gene segments by using the IMGT
database (Giudicelli et al., 2006). Downstream analysis was performed
as reported previously (Perry et al., 2014). See also Fig. S5 (A and B).
In vitro Treg cell suppression assay

CD25−CD4+CD8− conventional CD4+ T cells (2.5 × 104 cells) sorted
from BoyJ (CD45.1+) mice spleens were labeled with Celltrace Violet (CTV; Invitrogen) and mixed with Treg cells (CD25+CD4+CD8−)
sorted from thymi of WT or MARCH1−/− mice to various ratios. The
cell mixtures were added with 104 beads conjugated with anti-CD3 and
anti-CD28 antibodies and cultured in 37°C for 3 d. The percentages
of CD45.1+ conventional CD4+ T cells with their CTV diluted were
determined by flow cytometry.
Treg cell–dependent suppression of wasting disease and IBD

Naive CD4+ T cells (CD45RBhiCD25−CD4+CD8−) were isolated from
WT mouse spleens and lymph nodes and injected into 9- to 12-wk14
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Flow cytometry data were analyzed by FlowJo. Graphs were drawn by
PRISM (GraphPad). Unpaired two-tailed Student’s t test was performed
to assess the significance unless stated otherwise. R v3.2.3 was used for
graphical and statistical analysis of TCR repertoire data. The R package
DESeq2 (v1.10.3) was used for differential TCR expression analysis, and
vegan (v2.3-5) for dimensional analysis, rarefaction, and visualization.
Online supplemental material

Fig. S1 shows the map of the MARCH1 exon6-targeting construct used
to generate MARCH1fl/fl mice. Fig. S2 shows the surface expression of
MHCII, CD86, CD80, and ICAM1 in thymic DCs of WT, MARCH1−/−,
or MHCIIK>R/K>R mice. Fig. S3 shows the association of MHCII with
the lipid raft in WT and MHCIIK>R/K>R DCs. Fig. S4 shows that the
excessive accumulation of CD86 in DCs does not alter the lipid raft or
tetraspanin web. Fig. S5 provides additional details related to the TCR
repertoire analysis and representative images of colonic inflammation
of the IBD mouse model.

Acknowledgments
We thank M. Onizawa and A. Ma for advise on the IBD mouse
model, C. Castellanos for critically reading the manuscript, and
I. Mellman for providing the MHCIIK>R/K>R mice.
This work was supported by National Institutes of Health
(GM105800 to J.-S. Shin) and University of California, San Francisco,
Sandler Asthma Basic Research Center (J.-S. Shin).
The authors declare no competing financial interests.
Author contributions: J. Oh and J.-S. Shin designed experiments
and wrote the manuscript. J. Oh, J.S.A. Perry, H. Pua, N. IrgensMöller, and J.-S. Shin performed experiments. J. Oh, J.-S. Shin,
J.S.A. Perry, and C.-S. Hsieh analyzed the data. S. Ishido provided MARCH1−/− mice.
Submitted: 22 November 2016
Revised: 25 October 2017
Accepted: 8 January 2018

Downloaded from jcb.rupress.org on February 13, 2018

Bone marrow cells were isolated from femurs and/or tibiae of the
donor mice. Recipient mice were lethally irradiated (1,200 rad)
and intravenously injected with 3–5 × 106 bone marrow cells. Mice
were examined 6 wk later.

old Rag1−/− mice (4–5 × 105 cells per mouse). Some mice were also
injected with Treg cells isolated from WT or MARCH1−/− mice thymi
(2–2.5 × 105 cells per mouse). Mice were weighed every 2–3 d. Mice
were euthanized on day 56, and distal colons were stained by using
hematoxylin and eosin. The pathology was scored as follows: mucosal damage (0, none; 1, discrete lymphoepithelial lesions; 2, diffuse crypt elongation; or 3, extensive crypt elongation or mucosal
ulceration), immune cell infiltration (0, none; 1, widely scattered leukocytes or focal aggregates; 2, confluent leukocytes extending into
submucosa with focal effacement of the mucosa; or 3, leukocyte infiltration with transmural extension), and crypt abscess (0, absent; or
1, present; Yamaji et al., 2012). Values for each slide were summed
for a total score of 0–7.
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Figure S1. Generation of MARCH1fl/fl CD11c-CRE mice. Shown are the maps of the MARCH1 exon6-targeting construct, loxP flanked allele, and CRE
recombined/deleted allele. Red arrows indicate the primer pair used to determine the efficiency of Cre-mediated recombination.

Figure S2. Surface expression of MHCII, B7 costimulatory molecules, and ICAM1 in thymic DCs. (A) DCs were isolated from WT or MARCH1−/− mouse
thymi and examined by flow cytometry. (B) DCs were isolated from WT or MHCIIK>R/K>R mouse thymi and examined by flow cytometry. Data represent two
independent experiments.

Figure S3. Association of MHCII with the lipid raft in WT and MHCII K–deficient DCs. BMDCs derived from WT or MHCIIK>R/K>R mice were lysed with
1% Brij58 and fractionated by sucrose density gradient centrifugation as described in our previous study (Shin et al., 2000). Western blot analysis was performed by using antibodies raised against MHCII or actin. Note that some of MHCII molecules were fractionated into the light buoyantdensity fractions (#4 and #5).
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Figure S4. Excessive accumulation of CD86 in DCs does not alter the lipid raft or tetraspanin web. BMDCs derived from WT mice were transduced with
retrovirus encoding CD86 (K>R) mutant along with cytosolic GFP. The surface level of CD86 in untransduced (GFP−) and transduced cells (GFP+) was
determined by flow cytometry (A). Cells were stained using antibodies directed against indicated molecules or CTxB (for GM1) and subsequently analyzed by flow cytometry (B).
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Figure S5. TCR repertoire analysis and pathology of IBD mouse model. (A) A table summarizing the TCR repertoire sequencing analysis. “>0.01% filtered
TCRs” indicates that the TCR reads present >0.01% in at least one mouse of either genotype. Those TCRs were then further filtered to be characterized as
“unique TCRs” if they were present in at least three of seven or eight mice in one genotype. (B) Principle component (PC) analysis of sequencing data. Treg
cells and non-Treg CD4+ thymocytes are analyzed separately. Each dot represents each mouse. Note that dots are segregated under PC1 by genotype
for both Treg cells and non-Treg CD4+ thymocytes. (C) Dot plot of unique non-Treg CD4+ thymocyte TCR frequencies in MARCH1−/− versus WT mice. Red
and blue dots indicate unique TCRs significantly diminished and enriched in MARCH1−/− mice, respectively (P < 0.075, Mann-Whitney U test). ND, not
detected. (D) The percentages of unique non-Treg CD4+ thymocyte TCR clones diminished or enriched significantly and more than fivefold in MARCH1−/−
mice. (E) Mice described in Fig. 8 D were euthanized on day 56 after cell transfer, and the distal colons were subjected to histological examination.
Representative microscopic images (200×) of hematoxylin and eosin–stained sections are shown.
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